Leah J. Witt, MD: Hello. I'm Dr Leah Witt. Welcome to season one of Medscape InDiscussion, chronic obstructive pulmonary disease (COPD) podcast series. Today we're talking medications, especially ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

Please provide your email address to receive an email when new articles are posted on . Less than 40% of the studied veteran cohort were adherent to their inhaled COPD medications. Adherence was found ...

Starting January 1, a drug that thousands of patients depend on to help them breathe will disappear from pharmacy shelves, and doctors are concerned patients may have delays switching to alternatives ...

Yupelri (revefenacin) is a prescription nebulizer used to treat chronic obstructive pulmonary disease (COPD). Yupelri’s cost may depend on factors such as your dosage, whether you have health ...

Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the asthma medications from AstraZeneca and Boehringer Ingelheim. Following ...

SPL84 is administered directly into the lungs where it is taken up by the cells and is expected to drive the production of fully functional CFTR proteins. The Food and Drug Administration (FDA) has ...

Switching from a metered-dose to a dry-powder inhaler after a formulary change increased emergency department visits and hospitalizations in people with COPD or asthma. The absolute changes in risk ...

DUBLIN--(BUSINESS WIRE)--The "Inhalation and Nasal Spray Generic Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Inhalation and ...

ORLANDO, Fla.--(BUSINESS WIRE)--AireHealth, an innovative digital health company empowering and improving healthy living through affordable treatments, symptom tracking and early detection of ...

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its ...